Results 211 to 220 of about 66,826 (280)

A Case Study and Review of the Literature on IgA Nephropathy in Crohn's Disease

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT IgA nephropathy (IgAN) is the most frequently reported glomerular disease associated with inflammatory bowel disease (IBD), particularly Crohn's disease (CD), although pediatric cases remain rare. We report IgAN in a 16‐year‐old male with CD following intestinal surgery and during long‐term infliximab therapy, with renal impairment occurring ...
Giovanna Fernanda Vazzana, Alessia Romano, Chiara Casuscelli, Alberto La Spada, Domenico Santoro, Roberto Chimenz, Claudio Romano   +6 more
wiley   +1 more source

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis. [PDF]

JMIR Bioinform Biotechnol
Pachón-Suárez DI, Mejía-Salgado G, Correa O, Sánchez A, Munera M, de-la-Torre A.   +5 more
europepmc   +1 more source

Acitretin-induced psoriasis and Darier disease treated with adalimumab. [PDF]

An Bras Dermatol
Sánchez-Báez DJ, Mercader-Salvans J, Santos E Silva Caldeira-Marques ML, Pestana-Eliche MDM.   +3 more
europepmc   +1 more source

Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
This review synthesizes current mechanistic and clinical evidence on IL‐6 inhibitors, particularly sarilumab and tocilizumab, concerning their effect on pain in RA. ABSTRACT Rheumatoid arthritis (RA) is an autoimmune systemic disease in which pain remains a major and often refractory symptom even after clinical remission of the disease.
Andrej Belančić, Seher Sener, Almir Fajkić, Ines Potočnjak, Mirjana Stanić Benić, Marijana Vučković, Yusuf Ziya Sener, Marija Rogoznica Pavlović, Antonio Markotić, Josipa Radić, Mislav Radić   +10 more
wiley   +1 more source

Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report. [PDF]

SAGE Open Med Case Rep
Lozito A, Baravalle S, Poddine G, Colato C, Carletto A, Fracassi E, Bellinato F, Girolomoni G, Gisondi P.   +8 more
europepmc   +1 more source

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab‐Atto

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Consistent with previously demonstrated similarity of biosimilar ABP 501 (adalimumab‐atto) with adalimumab reference product, this study in healthy adults demonstrates the pharmacokinetic, safety, and immunogenicity similarity of a high‐concentration formulation (100 mg/mL) of ABP 501 with the original 50mg/mL formulation.
Vincent Chow, Muhan Zhou, Daniel T. Mytych, Alexander Colbert, Mieke Jill Miller, Iwona Wala, Ahad Sabet, Waldemar Radziszewski   +7 more
wiley   +1 more source

Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

United European Gastroenterology Journal, Volume 14, Issue 3, April 2026.
ABSTRACT Background and Aims Vedolizumab has become the preferred first‐line advanced therapy in ulcerative colitis (UC). However, the optimal second‐line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second‐line therapies after first‐line vedolizumab.
Louis Calméjane, Catherine Reenaers, Claire Gay, Aurélien Amiot, Alexandre Nuzzo, Lucine Vuitton, Calina Atanasiu, Carmen Stefanescu, Romain Altwegg, Lucas Guillo, Mélanie Serrero, Guillaume Bouguen, Maria Nachury, Guillaume Le Cosquer, Xavier Roblin, Vered Abitbol, Nassim Hammoudi, Marion Simon, Mathurin Fumery, Guillaume Savoye, Alban Benezech, Maryan Cavicchi, Maeva Charkaoui, Anthony Buisson, Bénédicte Caron, Benoît Coffin, Sophie Geyl, Félix Goutorbe, Marianne Hupé, Mathias Vidon, David Laharie, Julien Kirchgesner, Mathieu Uzzan, on behalf ofthe GETAID‐AFTER‐VEDO Study Group   +33 more
wiley   +1 more source

Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia. [PDF]

J Cachexia Sarcopenia Muscle
Qi H, Zhang XW, Zhang ZY, Ou SS, Gao YL, Tian D, Jiang YN, Min XR, Zhao AT, Zou JM, Zeng JS, Pu QY, Yang RC, Zeng N.   +13 more
europepmc   +1 more source

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non‐Biologic Treatment: Results From an Overlap Weighting Analysis in High‐Risk Patients With Axial Spondyloarthritis

International Journal of Rheumatic Diseases, Volume 29, Issue 4, April 2026.
ABSTRACT Objective Acute anterior uveitis (AAU) is the most common extra‐musculoskeletal manifestation of axial spondyloarthritis (axSpA). This study compared the effect of the tumor necrosis factor inhibitor (TNFi) certolizumab pegol (CZP) with standard non‐biologic care, on AAU flare rate in patients with axSpA and high risk of recurrent uveitis ...
Nigil Haroon, Zeynep Baskurt, Tina Chim, Robert D. Inman, Thomas Kumke, Rachel Tham, Mindy Kim, Irene van der Horst‐Bruinsma, Lianne S. Gensler   +8 more
wiley   +1 more source

Prediction and Characterization of Glycated Peptides and Proteins using Hydrophilic Interaction Liquid Chromatography coupled with Mass Spectrometry (HILIC-MS). [PDF]

J Biomol Tech
Priya S, Kowalski EL, Popov M, Orlando R.   +3 more
europepmc   +1 more source